The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol

被引:200
作者
Das, Surajit [1 ]
Lin, Hai-Shu [1 ]
Ho, Paul C. [1 ]
Ng, Ka-Yun [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore
关键词
aqueous solubility; bioavailability; dose manipulation; pharmacokinetics; resveratrol;
D O I
10.1007/s11095-008-9677-1
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Purpose. This study aimed at the investigation of the impact of aqueous solubility and dose manipulation on the pharmacokinetics of resveratrol. Methods. Water soluble intravenous and oral formulations of resveratrol were prepared with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and randomly methylated-beta-cyclodextrin (RM-beta-CD), respectively. Sodium salt and suspension of resveratrol in carboxymethyl cellulose (CMC) were used as the reference intravenous and oral formulations, respectively. The pharmacokinetics of resveratrol was assessed in Sprague-Dawley rats. Plasma resveratrol concentrations were measured by high performance liquid chromatography (HPLC). Results. Both HP-beta-CD and RM-beta-CD enhanced the aqueous solubility of resveratrol. After intravenous administration, rapid elimination of resveratrol was observed at all tested doses (5, 10, and 25 mg kg(-1)) regardless of formulation types; with non-linear elimination occurring at the dose of 25 mg kg(-1). RM-beta-CD significantly increased the maximal plasma concentration of orally administered resveratrol, but, it did not increase the oral bioavailability in comparison with the CMC suspension. Furthermore, the oral bioavailability remained unchanged among all tested doses (15, 25, and 50 mg kg(-1)). Conclusions. Aqueous solubility barrier might affect the speed but not the extent of resveratrol absorption. Further, dose manipulation (up to 50 mg kg(-1)) did not have a significant impact on the oral bioavailability of resveratrol.
引用
收藏
页码:2593 / 2600
页数:8
相关论文
共 32 条
[1]
Andlauer W, 2000, DRUG EXP CLIN RES, V26, P47
[2]
Resveratrol improves health and survival of mice on a high-calorie diet [J].
Baur, Joseph A. ;
Pearson, Kevin J. ;
Price, Nathan L. ;
Jamieson, Hamish A. ;
Lerin, Carles ;
Kalra, Avash ;
Prabhu, Vinayakumar V. ;
Allard, Joanne S. ;
Lopez-Lluch, Guillermo ;
Lewis, Kaitlyn ;
Pistell, Paul J. ;
Poosala, Suresh ;
Becker, Kevin G. ;
Boss, Olivier ;
Gwinn, Dana ;
Wang, Mingyi ;
Ramaswamy, Sharan ;
Fishbein, Kenneth W. ;
Spencer, Richard G. ;
Lakatta, Edward G. ;
Le Couteur, David ;
Shaw, Reuben J. ;
Navas, Placido ;
Puigserver, Pere ;
Ingram, Donald K. ;
de Cabo, Rafael ;
Sinclair, David A. .
NATURE, 2006, 444 (7117) :337-342
[3]
Therapeutic potential of resveratrol:: the in vivo evidence [J].
Baur, Joseph A. ;
Sinclair, David A. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (06) :493-506
[4]
Host-guest interaction study of resveratrol with natural and modified cyclodextrins [J].
Bertacche, Vittorio ;
Lorenzi, Natascia ;
Nava, Donatella ;
Pini, Elena ;
Sinco, Chiara .
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, 2006, 55 (3-4) :279-287
[5]
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent [J].
Boocock, David J. ;
Faust, Guy E. S. ;
Patel, Ketan R. ;
Schinas, Anna M. ;
Brown, Victoria A. ;
Ducharme, Murray P. ;
Booth, Tristan D. ;
Crowell, James A. ;
Perloff, Marjorie ;
Gescher, Andreas J. ;
Steward, William P. ;
Brenner, Dean E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (06) :1246-1252
[6]
Chan OH, 1996, DRUG DISCOV TODAY, V1, P461
[7]
*CLINICALTRIAL GOV, SERV US NAT I HLTH
[8]
Cyclodextrin-based pharmaceutics: Past, present and future [J].
Davis, ME ;
Brewster, ME .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1023-1035
[9]
Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum [J].
De Santi, C ;
Pietrabissa, A ;
Spisni, R ;
Mosca, F ;
Pacifici, GM .
XENOBIOTICA, 2000, 30 (06) :609-617
[10]
Resveratrol as a chemopreventive agent:: A promising molecule for fighting cancer [J].
Delmas, D ;
Lançon, A ;
Colin, D ;
Jannin, B ;
Latruffe, N .
CURRENT DRUG TARGETS, 2006, 7 (04) :423-442